Mysimba: A Clinically Proven Weight Management Aid
Mysimba
| Product dosage: 90mg/8mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 10 | $7.00 | $70.00 (0%) | 🛒 Add to cart |
| 20 | $6.00 | $140.00 $120.00 (14%) | 🛒 Add to cart |
| 30 | $5.33 | $210.00 $160.00 (24%) | 🛒 Add to cart |
| 60 | $3.33 | $420.00 $200.00 (52%) | 🛒 Add to cart |
| 90 | $2.77 | $630.00 $249.00 (60%) | 🛒 Add to cart |
| 120 | $2.56 | $840.00 $307.00 (63%) | 🛒 Add to cart |
| 180 | $2.20 | $1260.00 $396.00 (69%) | 🛒 Add to cart |
| 270 | $2.00 | $1890.00 $540.00 (71%) | 🛒 Add to cart |
| 360 | $1.91
Best per tab | $2520.00 $688.00 (73%) | 🛒 Add to cart |
Mysimba is a prescription-only medication designed to support sustainable weight management in adults with obesity or overweight with weight-related comorbidities. It combines two active substances, naltrexone hydrochloride and bupropion hydrochloride, in an extended-release formulation that works on areas of the brain involved in appetite control and reward. This dual-action mechanism helps reduce hunger and cravings, supporting adherence to a reduced-calorie diet and increased physical activity. Mysimba is indicated as an adjunct to lifestyle modifications and should be used under medical supervision as part of a comprehensive weight management plan.
Features
- Contains naltrexone HCl 8 mg and bupropion HCl 90 mg per tablet
- Extended-release oral formulation
- Titrated dosing regimen over four weeks
- Requires prescription and medical supervision
- Packaged in high-density polyethylene (HDPE) bottles with child-resistant caps
Benefits
- Supports clinically significant weight loss when combined with lifestyle modifications
- Helps reduce feelings of hunger and food cravings
- Addresses both physiological and behavioural aspects of weight management
- May improve metabolic parameters in patients with weight-related comorbidities
- Provides a non-surgical option for weight management
- Can be used long-term under appropriate medical supervision
Common use
Mysimba is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia. It is typically prescribed when lifestyle modifications alone have proven insufficient for achieving meaningful weight loss. Treatment response should be evaluated after 16 weeks; continuation is recommended only for patients who have achieved at least 5% weight loss from baseline.
Dosage and direction
The recommended dosage must be escalated over the first four weeks to minimise the risk of adverse effects. Week 1: One tablet (8 mg naltrexone/90 mg bupropion) taken orally in the morning. Week 2: One tablet in the morning and one tablet in the evening. Week 3: Two tablets in the morning and one tablet in the evening. Week 4 and maintenance: Two tablets in the morning and two tablets in the evening. Tablets should be swallowed whole and not crushed, divided, or chewed. The maximum daily dose is 32 mg naltrexone/360 mg bupropion. Mysimba should be taken with food to reduce the incidence of nausea.
Precautions
Patients should be monitored for increases in blood pressure and heart rate, particularly during the initial titration period. Regular assessment of mental health status is recommended due to the potential for neuropsychiatric adverse reactions. Caution is advised in patients with hepatic or renal impairment. Mysimba may lower the seizure threshold; use with caution in patients with predisposing factors for seizures. Abrupt discontinuation should be avoided; gradual dose reduction is recommended. Patients should be advised that Mysimba contains bupropion, which may cause insomnia if taken too close to bedtime.
Contraindications
Mysimba is contraindicated in patients with uncontrolled hypertension, seizure disorders, or history of seizures. It must not be used during or within 14 days of taking monoamine oxidase inhibitors (MAOIs). Additional contraindications include pregnancy, breastfeeding, end-stage renal disease, severe hepatic impairment, eating disorders (current or history of), and concomitant use with other bupropion-containing products. It is contraindicated in patients with known hypersensitivity to naltrexone, bupropion, or any excipients in the formulation.
Possible side effects
Common adverse reactions (≥5%) include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhoea. These effects are typically transient and most prevalent during the titration period. Serious side effects may include increased blood pressure, heart rate elevations, seizures, angle-closure glaucoma, liver toxicity, allergic reactions, and neuropsychiatric events including suicidal thoughts and behaviours. Patients should be instructed to report any unusual symptoms, particularly cardiovascular or neuropsychiatric concerns, to their healthcare provider promptly.
Drug interactions
Mysaltrexone/bupropion may interact with drugs metabolised by CYP2D6, requiring dose adjustment of concomitant medications. Concurrent use with other dopaminergic or noradrenergic agents may increase the risk of adverse effects. Avoid concomitant use with MAOIs, other bupropion-containing products, and drugs that lower seizure threshold. Caution is advised with drugs that affect hepatic metabolism. Alcohol consumption should be minimised or avoided due to increased risk of neuropsychiatric adverse events. Healthcare providers should review all concomitant medications, including over-the-counter products and herbal supplements.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is close to the time of the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take extra tablets to make up for a missed dose. Doubling the dose may increase the risk of adverse effects, particularly nausea or dizziness. If multiple doses are missed, consultation with a healthcare provider is recommended before resuming treatment, as dose retitration may be necessary.
Overdose
Overdose may manifest as seizures, hallucinations, loss of consciousness, tachycardia, or electrocardiogram changes. In case of suspected overdose, immediate medical attention is required. Management should include supportive measures and symptomatic treatment. Activated charcoal may be considered if ingestion was recent. Seizures should be treated with benzodiazepines; ECG monitoring is recommended. Due to the extended-release formulation, delayed onset and prolonged duration of symptoms are possible. Patients should be advised to store Mysimba securely to prevent accidental ingestion by others.
Storage
Store at room temperature (15-30°C) in the original container with the cap tightly closed. Protect from light and moisture. Keep out of reach of children and pets. Do not transfer tablets to other containers. Discard any unused medication appropriately according to local regulations. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is provided for educational purposes only and does not replace professional medical advice. Mysimba is a prescription medication that should be used only under the supervision of a qualified healthcare provider. Individual results may vary. Patients should discuss their medical history, current medications, and treatment goals with their healthcare provider before initiating therapy. The full prescribing information should be consulted for complete details regarding use, warnings, and precautions.
Reviews
Clinical trials demonstrate that Mysimba, when combined with lifestyle intervention, produces significantly greater weight loss compared to placebo. In a 56-week controlled study, approximately 42-48% of patients achieved ≥5% weight loss, with about 20-25% achieving ≥10% weight loss. Patients reported improvements in quality of life measures and eating behaviour control. Real-world evidence supports maintained weight loss with continued therapy under medical supervision. Healthcare providers note the importance of proper patient selection, dose titration, and ongoing monitoring for optimal outcomes and safety.